Elevance Health, Inc. $ELV Shares Purchased by Lansforsakringar Fondforvaltning AB publ

Lansforsakringar Fondforvaltning AB publ lifted its stake in Elevance Health, Inc. (NYSE:ELV) by 3.2% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 72,614 shares of the company’s stock after purchasing an additional 2,280 shares during the quarter. Lansforsakringar Fondforvaltning AB publ’s holdings in Elevance Health were worth $23,463,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Physician Wealth Advisors Inc. lifted its stake in shares of Elevance Health by 331.6% during the third quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock worth $26,000 after buying an additional 63 shares during the period. Activest Wealth Management raised its stake in Elevance Health by 66.7% in the 3rd quarter. Activest Wealth Management now owns 85 shares of the company’s stock worth $27,000 after acquiring an additional 34 shares during the last quarter. Rossby Financial LCC lifted its position in Elevance Health by 110.0% during the 3rd quarter. Rossby Financial LCC now owns 84 shares of the company’s stock worth $28,000 after acquiring an additional 44 shares during the period. Vermillion & White Wealth Management Group LLC grew its stake in Elevance Health by 94.9% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 76 shares of the company’s stock valued at $30,000 after purchasing an additional 37 shares during the last quarter. Finally, BOK Financial Private Wealth Inc. purchased a new stake in Elevance Health during the 2nd quarter valued at about $32,000. Hedge funds and other institutional investors own 89.24% of the company’s stock.

Wall Street Analyst Weigh In

ELV has been the subject of a number of research reports. Wolfe Research set a $425.00 target price on Elevance Health and gave the stock an “outperform” rating in a report on Thursday, January 8th. JPMorgan Chase & Co. upped their price objective on shares of Elevance Health from $394.00 to $397.00 and gave the company an “overweight” rating in a report on Monday, February 2nd. Sanford C. Bernstein reduced their target price on shares of Elevance Health from $431.00 to $409.00 and set an “outperform” rating for the company in a report on Friday, January 30th. TD Cowen restated a “buy” rating on shares of Elevance Health in a research report on Wednesday, November 26th. Finally, Truist Financial reduced their price objective on Elevance Health from $400.00 to $390.00 and set a “buy” rating for the company in a research note on Monday, February 2nd. Twelve equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $390.55.

Elevance Health Price Performance

Shares of Elevance Health stock opened at $342.95 on Monday. The firm has a market cap of $75.69 billion, a PE ratio of 13.65, a P/E/G ratio of 1.90 and a beta of 0.50. Elevance Health, Inc. has a twelve month low of $273.71 and a twelve month high of $458.75. The company has a quick ratio of 1.54, a current ratio of 1.54 and a debt-to-equity ratio of 0.70. The business has a 50-day moving average price of $352.37 and a 200 day moving average price of $334.71.

Elevance Health (NYSE:ELV) last issued its quarterly earnings data on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, beating the consensus estimate of $3.10 by $0.23. The company had revenue of $49.31 billion for the quarter, compared to analyst estimates of $49.52 billion. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.Elevance Health’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same period last year, the company earned $3.84 earnings per share. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Sell-side analysts predict that Elevance Health, Inc. will post 33.96 earnings per share for the current fiscal year.

Elevance Health Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Stockholders of record on Tuesday, March 10th will be given a $1.72 dividend. This represents a $6.88 annualized dividend and a dividend yield of 2.0%. This is a positive change from Elevance Health’s previous quarterly dividend of $1.71. The ex-dividend date is Tuesday, March 10th. Elevance Health’s dividend payout ratio (DPR) is 27.23%.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.